FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588339858> ?p ?o ?g. }

• W2588339858 endingPage "vi138" @default.
• W2588339858 startingPage "vi137" @default.
• W2588339858 abstract "Glioblastoma (GBM) is an aggressive neoplasm that invariably recurs despite recent advances in therapy. Here, we describe a series of patients treated with Tumor Treating Fields (TTFields) who developed brain stem recurrence post TTFields therapy. TTFields is an FDA-approved therapeutic option for recurrent supratentorial GBM, as a monotherapy after surgical and radiation options have been exhausted, and recently in combination with maintenance temozolomide (TMZ) for treatment of newly diagnosed adult GBM patients. TTFields is a non-invasive, regional antimitotic treatment modality, alternating electric fields to tumors, through transducer arrays placed on the scalp of GBM patients. TTFields disrupts normal cell division processes, selectively targeting proliferating cancer cells. Some mechanisms of escape have been described (eg, out of field recurrence). It is known that the brainstem dose not receive high intensity TTFields due to anatomic limitations of the treatment delivery. Six cases were obtained by retrospective chart review from multiple providers that have experience with prescribing and planning treatment with TTFields. Clinical and radiographic reviews were performed after de-identification of patient records. Cases were compared according to demographics, tumor location and molecular genetics. Patients were a median age of 60 years old (range 52-69), who underwent standard therapy including surgery radiation, adjuvant TMZ, and subsequently received TTFields. There were various tumor locations at baseline presentation. Median duration of TTFields prior to development of brainstem recurrence was 3.5 months, range 2-5 months. Most patients discontinued treatment on TTFields after recurrence. Treatment options for patients with GBM are limited, however TTFields have been shown to improve OS when added to TMZ. TTFields can only be delivered in therapeutic intensities to the supratentorial brain. These out-of-field recurrences are of concern, given the stable primary supratentorial tumor. Further investigation is warranted to improve treatment of the entire nervous system with TTFields." @default.
• W2588339858 created "2017-02-24" @default.
• W2588339858 creator A5012927658 @default.
• W2588339858 creator A5021790010 @default.
• W2588339858 creator A5029581528 @default.
• W2588339858 creator A5032503170 @default.
• W2588339858 creator A5041536073 @default.
• W2588339858 creator A5056817906 @default.
• W2588339858 creator A5074754509 @default.
• W2588339858 date "2016-11-01" @default.
• W2588339858 modified "2023-09-26" @default.
• W2588339858 title "NIMG-61. PATTERNS OF GLIOBLASTOMA RECURRENCE IN LOW FIELD INTENSITY REGIONS DURING TTFIELDS TREATMENT" @default.
• W2588339858 doi "https://doi.org/10.1093/neuonc/now212.572" @default.
• W2588339858 hasPublicationYear "2016" @default.
• W2588339858 type Work @default.
• W2588339858 sameAs 2588339858 @default.
• W2588339858 citedByCount "0" @default.
• W2588339858 crossrefType "journal-article" @default.
• W2588339858 hasAuthorship W2588339858A5012927658 @default.
• W2588339858 hasAuthorship W2588339858A5021790010 @default.
• W2588339858 hasAuthorship W2588339858A5029581528 @default.
• W2588339858 hasAuthorship W2588339858A5032503170 @default.
• W2588339858 hasAuthorship W2588339858A5041536073 @default.
• W2588339858 hasAuthorship W2588339858A5056817906 @default.
• W2588339858 hasAuthorship W2588339858A5074754509 @default.
• W2588339858 hasBestOaLocation W25883398581 @default.
• W2588339858 hasConcept C121608353 @default.
• W2588339858 hasConcept C126322002 @default.
• W2588339858 hasConcept C141071460 @default.
• W2588339858 hasConcept C143998085 @default.
• W2588339858 hasConcept C2777389519 @default.
• W2588339858 hasConcept C509974204 @default.
• W2588339858 hasConcept C71924100 @default.
• W2588339858 hasConceptScore W2588339858C121608353 @default.
• W2588339858 hasConceptScore W2588339858C126322002 @default.
• W2588339858 hasConceptScore W2588339858C141071460 @default.
• W2588339858 hasConceptScore W2588339858C143998085 @default.
• W2588339858 hasConceptScore W2588339858C2777389519 @default.
• W2588339858 hasConceptScore W2588339858C509974204 @default.
• W2588339858 hasConceptScore W2588339858C71924100 @default.
• W2588339858 hasIssue "suppl_6" @default.
• W2588339858 hasLocation W25883398581 @default.
• W2588339858 hasLocation W25883398582 @default.
• W2588339858 hasOpenAccess W2588339858 @default.
• W2588339858 hasPrimaryLocation W25883398581 @default.
• W2588339858 hasRelatedWork W2002120878 @default.
• W2588339858 hasRelatedWork W2003938723 @default.
• W2588339858 hasRelatedWork W2029933304 @default.
• W2588339858 hasRelatedWork W2034544297 @default.
• W2588339858 hasRelatedWork W2047967234 @default.
• W2588339858 hasRelatedWork W2118496982 @default.
• W2588339858 hasRelatedWork W2128503410 @default.
• W2588339858 hasRelatedWork W2439875401 @default.
• W2588339858 hasRelatedWork W3194058763 @default.
• W2588339858 hasRelatedWork W2525756941 @default.
• W2588339858 hasVolume "18" @default.
• W2588339858 isParatext "false" @default.
• W2588339858 isRetracted "false" @default.
• W2588339858 magId "2588339858" @default.
• W2588339858 workType "article" @default.